ArticleMolecular therapy oncolytics2020
miR-155 Accelerates the Growth of Human Liver Cancer Cells by Activating CDK2 via Targeting H3F3A.
Article in Molecular therapy oncolytics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- miR-215-5p Suppresses Proliferation/Cell-Cycle Progression and Promotes Apoptosis via Targeting CTCF in Goat Mammary Epithelial Cells.Animals : an open access journal from MDPI · 2026Article
- Mechanisms of FOXK1-regulated glycolipid metabolism in mediating TOX-induced histone lactylation to promote CD8⁺ T cell exhaustion in high-grade serous ovarian cancer.Scientific reports · 2026Article
- From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis.Medical oncology (Northwood, London, England) · 2025Review
- The Role of MAPK12 in Prognosis of Patients With Liver Cancer and Effects on Stemness Characteristics.Stem cells international · 2025Article
- Pump-free SERS microfluidic chip based on an identification-competition strategy for ultrasensitive and efficient simultaneous detection of liver cancer-related microRNAs.Biomedical optics express · 2024Article
- Inhibition of MiR-155 Using Exosomal Delivery of Antagomir Can Up-RegulateEndocrine, metabolic & immune disorders drug targets · 2024Article
- Article
- MicroRNAs in Cancer and Cardiovascular Disease.Cells · 2022Review
- A review on the role of cyclin dependent kinases in cancers.Cancer cell international · 2022Review
- Review
- MicroRNA-501-3p inhibits the proliferation of kidney cancer cells by targeting WTAP.Cancer medicine · 2021Article
- Role of Nitric Oxide in Gene Expression Regulation during Cancer: Epigenetic Modifications and Non-Coding RNAs.International journal of molecular sciences · 2021Review
- Targeting Long Non-coding RNA to Therapeutically Regulate Gene Expression in Cancer.Molecular therapy. Nucleic acids · 2020Review
- MiR-9-1 Suppresses Cell Proliferation and Promotes Apoptosis by Targeting UHRF1 in Lung Cancer.Technology in cancer research & treatmentArticle
- Current Status and Prospects of Clinical Treatment of Osteosarcoma.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
miR-155 is associated with the promotion of tumorigenesis. Herein, we indicate that abnormal miR-155 was negatively correlated with the expression of P21WAF1/Cip1. Our results suggest that miR-155 alters the transcriptome and inhibits the expression of H3F3A in liver cancer cells. Therefore, miR-155 inhibits the methylation modification of histone H3 on the 27
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.